Quizartinib Boosts AML Survival, Regardless of SCT Quizartinib Boosts AML Survival, Regardless of SCT
Adding quizartinib to standard induction chemotherapy significantly improves overall survival in patients with newly diagnosed acute myeloid leukemia regardless of prior stem cell transplantation.MDedge News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - July 19, 2023 Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news
Spleen Volume Linked to Outcome After HSCT for Leukemia Patients
WEDNESDAY, July 19, 2023 -- For patients with acute myeloid leukemia (AML), higher spleen volume at the time of hematopoietic stem cell transplant (HSCT) is associated with inferior overall survival and an increased incidence of nonrelapse mortality... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 19, 2023 Category: Pharmaceuticals Source Type: news
FDA Strikes at Yet Another Birth Tissue Company
(MedPage Today) -- The FDA is again clamping down on unapproved stem cell therapies, this time with a warning letter expressing safety and regulatory compliance concerns involving umbilical cord cellular products marketed by Regenative Labs of... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 19, 2023 Category: American Health Source Type: news
Study sheds light on origins, changeability of blood stem cells in humans
A group of researchers at Yale School of Medicine has found that levels of diversity of blood stem cells are determined during the development of the embryo. (Source: Yale Science and Health News)
Source: Yale Science and Health News - July 17, 2023 Category: Universities & Medical Training Source Type: news
Student, 20, given weeks to live after lower back pain revealed to be rare blood cancer
Despite chemotherapy and a stem cell transplant, doctors have said his condition is terminal. (Source: Daily Express - Health)
Source: Daily Express - Health - July 17, 2023 Category: Consumer Health News Source Type: news
How Are Keloids Treated?
Discussion
Wound healing is a complex process and abnormalities are common. Hypertrophic or keloid scarring are the two types of excessive scarring with both having excessive scar tissue that is elevated above the normal skin. Hypertrophic scarring occurs usually only within the wound and can regress. They are common after burns and develop within 3 months of skin injury. Keloid scarring spreads beyond the original wound and does not regress, and often recur. They can occur even 1 year after injury.
Keloids have an incidence of 5-15%. “Compared to normal fibroblasts, keloidal fibroblasts have longer lives, higher pro...
Source: PediatricEducation.org - July 17, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
B.C. family searches for stem cell donor to save child with rare neurological disease
As the Funk family considers their next steps to save their seven-year-old, those who have seen the disease first-hand say Canada should consider screening for the condition at birth and improve out-of-province coverage options. (Source: CBC | Health)
Source: CBC | Health - July 16, 2023 Category: Consumer Health News Tags: News/Canada/British Columbia Source Type: news
New Human Embryo Models Spark Needless Controversy
Recent news of complex embryo models revived debates over stem cells and human cloning. But biology says there’s nothing to worry about (Source: Scientific American Topic - Stem Cell Research)
Source: Scientific American Topic - Stem Cell Research - July 13, 2023 Category: Stem Cells Authors: Insoo Hyun Tags: Biology Genetics Source Type: news
Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Media News - July 13, 2023 Category: Pharmaceuticals Source Type: news
Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Investor Update - July 13, 2023 Category: Pharmaceuticals Source Type: news
Stem Cell Medical Tourism Leads to Meningitis in MS Patient
(MedPage Today) -- A woman with multiple sclerosis (MS) who had intrathecal injections of umbilical cord stem cells in Mexico ended up with a severe Mycobacterium abscessus infection that took weeks to identify and treat, according to a case study... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 13, 2023 Category: American Health Source Type: news
BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer
Dr. Dagher has extensive biopharma industry expertise in the development and approval of treatments for challenging neurological and rare diseases
NEW YORK, July 12, 2023 -- (Healthcare Sales & Marketing Network) -- BrainStorm Cell Therapeutics Inc. (N... Regenerative Medicine, Personnel BrainStorm Cell Therapeutics, NurOwn, stem cell (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 12, 2023 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
Columvi is the first CD20xCD3 T-cell-engaging bispecific antibody available in Europe to treat the most common and aggressive form of lymphomaApproval is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete responses in people with heavily pre-treated or refractory diffuse large B-cell lymphoma1Columvi is given for a fixed period of time and made to be readily available, providing patients with a treatment end date and treatment-free periodBasel, 11 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) ha...
Source: Roche Media News - July 11, 2023 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
Columvi is the first CD20xCD3 T-cell-engaging bispecific antibody available in Europe to treat the most common and aggressive form of lymphomaApproval is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete responses in people with heavily pre-treated or refractory diffuse large B-cell lymphoma1Columvi is given for a fixed period of time and made to be readily available, providing patients with a treatment end date and treatment-free periodBasel, 11 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) ha...
Source: Roche Investor Update - July 11, 2023 Category: Pharmaceuticals Source Type: news
CAR T Cells Derived From Stem Cells Open Door To Universal Donor Cell Lines
Induced pluripotent stem cells (iPSC), a continuing muse in cell therapy research, could potentially be used to improve flaws associated with conventional CAR T therapy. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 10, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
